{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:05:41Z","timestamp":1790867141920,"version":"4.1.0"},"reference-count":41,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2009,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The immune response elicited by LC16m8, a candidate smallpox vaccine that was developed in Japan by cold selection during serial passage of the Lister vaccine virus in primary rabbit kidney cells, was compared to Dryvax in a mouse model. LC16m8 carries a mutation resulting in the truncation of the B5 protein, an important neutralizing target of the extracellular envelope form of vaccinia virus (EV). LC16m8 elicited a broad-spectrum immunoglobulin G (IgG) response that neutralized both EV and the intracellular mature form of vaccinia virus and provoked cell-mediated immune responses, including the activation of CD4\n            <jats:sup>+<\/jats:sup>\n            and CD8\n            <jats:sup>+<\/jats:sup>\n            cells, similarly to Dryvax. Mice inoculated with LC16m8 had detectable but low levels of anti-B5 IgG compared to Dryvax, but both Dryvax and LC16m8 sera neutralized vaccinia virus EV in vitro. A truncated B5 protein (\u223c8 kDa) was expressed abundantly in LC16m8-infected cells, and both murine immune sera and human vaccinia virus immunoglobulin recognized the truncated recombinant B5 protein in antigen-specific enzyme-linked immunosorbent assays. At a high-dose intranasal challenge (100 or 250 50% lethal doses), LC16m8 and Dryvax conferred similar levels of protection against vaccinia virus strain WR postvaccination. Taken together, the results extend our current understanding of the protective immune responses elicited by LC16m8 and indicate that the relative efficacy in a mouse model rivals that of previously licensed smallpox vaccines.\n          <\/jats:p>","DOI":"10.1128\/cvi.00040-09","type":"journal-article","created":{"date-parts":[[2009,7,16]],"date-time":"2009-07-16T01:44:51Z","timestamp":1247708691000},"page":"1261-1271","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":30,"title":["Comparative Evaluation of the Immune Responses and Protection Engendered by LC16m8 and Dryvax Smallpox Vaccines in a Mouse Model"],"prefix":"10.1128","volume":"16","author":[{"given":"Clement A.","family":"Meseda","sequence":"first","affiliation":[{"name":"Laboratory of DNA Viruses, Division of Viral Products, HFM-457, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, Maryland 20852"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne E.","family":"Mayer","sequence":"additional","affiliation":[{"name":"Laboratory of DNA Viruses, Division of Viral Products, HFM-457, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, Maryland 20852"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arunima","family":"Kumar","sequence":"additional","affiliation":[{"name":"Laboratory of DNA Viruses, Division of Viral Products, HFM-457, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, Maryland 20852"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alonzo D.","family":"Garcia","sequence":"additional","affiliation":[{"name":"Laboratory of DNA Viruses, Division of Viral Products, HFM-457, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, Maryland 20852"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Campbell","sequence":"additional","affiliation":[{"name":"Laboratory of DNA Viruses, Division of Viral Products, HFM-457, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, Maryland 20852"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Listrani","sequence":"additional","affiliation":[{"name":"Laboratory of DNA Viruses, Division of Viral Products, HFM-457, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, Maryland 20852"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jody","family":"Manischewitz","sequence":"additional","affiliation":[{"name":"Laboratory of Retrovirus Research, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa R.","family":"King","sequence":"additional","affiliation":[{"name":"Laboratory of Retrovirus Research, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Golding","sequence":"additional","affiliation":[{"name":"Laboratory of Retrovirus Research, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Merchlinsky","sequence":"additional","affiliation":[{"name":"Laboratory of DNA Viruses, Division of Viral Products, HFM-457, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, Maryland 20852"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry P.","family":"Weir","sequence":"additional","affiliation":[{"name":"Laboratory of DNA Viruses, Division of Viral Products, HFM-457, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, Maryland 20852"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.10.6260-6271.2005"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"6108","DOI":"10.1016\/j.vaccine.2008.09.007","volume":"26","year":"2008","unstructured":"Barefoot, B., N. J. Thornburg, D. H. Barouch, J.-S. Yu, C. Sample, R. E. Johnston, H. X. Liao, T. B. Kepler, B. F. Haynes, and E. Ramsburg. 2008. Comparison of multiple vaccine vectors in a single heterologous prime-boost trial. Vaccine26:6108-6118.","journal-title":"Vaccine"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.virol.2004.05.004","volume":"325","year":"2004","unstructured":"Bell, E., M. Shamim, J. C. Whitbeck, G. Sfyroera, J. D. Lambris, and S. N. Isaacs. 2004. Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology325:425-431.","journal-title":"Virology"},{"key":"e_1_3_2_5_2","first-page":"165","volume":"58","year":"1980","unstructured":"Breman, J. G., R. Kalisa, M. V. Steniowski, E. Zanotto, A. I. Gromyko, and I. Arita. 1980. Human monkeypox, 1970-79. Bull. W. H. O.58:165-182.","journal-title":"Bull. W. H. O."},{"key":"e_1_3_2_6_2","first-page":"537","volume":"52","year":"2003","unstructured":"Centers for Disease Control and Prevention. 2003. Multistate outbreak of monkeypox\u2014Illinois, Indiana, and Wisconsin. MMWR Morb. Mortal. Wkly. Rep.52:537-540.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1073\/pnas.262668999","volume":"100","year":"2003","unstructured":"Drexler, I., C. Staib, W. Kastenmuller, S. Stevanovic, B. Schmidt, F. A. Lemonnier, H. G. Rammensee, D. H. Busch, H. Bernhard, V. Erfle, and G. Sutter. 2003. Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines. Proc. Natl. Acad. Sci. USA100:217-222.","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1016\/j.vaccine.2005.03.029","volume":"24","year":"2006","unstructured":"Empig, C., J. R. Kenner, M. Perret-Gentil, B. E. Youree, E. Bell, A. Chen, M. Gurwith, K. Higgins, M. Lock, A. D. Rice, J. Schriewer, F. Sinangil, E. White, R. M. Buller, T. S. Dermody, S. N. Isaacs, and R. W. Moyer. 2006. Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge. Vaccine24:3686-3694.","journal-title":"Vaccine"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.19.10230-10237.2004"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1006\/viro.1998.9516","volume":"254","year":"1999","unstructured":"Galmiche, M. C., J. Goenaga, R. Wittek, and L. Rindisbacher. 1999. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology254:71-80.","journal-title":"Virology"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00050-07"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"6864","DOI":"10.1073\/pnas.0701451104","volume":"104","year":"2007","unstructured":"Golovkin, M., S. Spitsin, V. Andrianov, Y. Smirnov, Y. Xiao, N. Pogrebnyak, K. Markley, R. Brodzik, Y. Gleba, S. N. Isaacs, and H. Koprowski. 2007. Smallpox subunit vaccine produced in planta confers protection in mice. Proc. Natl. Acad. Sci. USA104:6864-6869.","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S0140-6736(05)70234-8","volume":"365","year":"2005","unstructured":"Greenberg, R. N., J. S. Kennedy, D. J. Clanton, E. A. Plummer, L. Hague, J. Cruz, F. A. Ennis, W. C. Blackwelder, and R. J. Hopkins. 2005. Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calf-lymph derived vaccine: a blind, single-centre, randomised controlled trial. Lancet365:398-409.","journal-title":"Lancet"},{"key":"e_1_3_2_14_2","first-page":"87","year":"1985","unstructured":"Hashizume, S., H. Yoshizawa, M. Morita, and K. Suzuki. 1985. Properties of attenuated mutant of vaccinia virus LC16m8, derived from Lister strain, p. 87-99. In G. V. Quinnan, Jr. (ed.), Vaccinia viruses as vectors for vaccine antigens. Elsevier Science Publishing Co., Inc., San Diego, CA.","journal-title":"Vaccinia viruses as vectors for vaccine antigens"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.4049\/jimmunol.177.4.2552","volume":"177","year":"2006","unstructured":"Heraud, J. M., Y. Edghill-Smith, V. Ayala, I. Kalisz, J. Parrino, V. S. Kalyanaraman, J. Manischewitz, L. R. King, A. Hryniewicz, C. J. Trindade, M. Hassett, W. P. Tsai, D. Venzon, A. Nalca, M. Vaccari, P. Silvera, M. Bray, B. S. Graham, H. Golding, J. W. Hooper, and G. Franchini. 2006. Subunit recombinant vaccine protects against monkeypox. J. Immunol.177:2552-2564.","journal-title":"J. Immunol."},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1006\/viro.1999.0096","volume":"266","year":"2000","unstructured":"Hooper, J. W., D. M. Custer, C. S. Schmaljohn, and A. L. Schmaljohn. 2000. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Virology266:329-339.","journal-title":"Virology"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.9.4433-4443.2004"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/infdis\/154.4.551","volume":"154","year":"1986","unstructured":"Jezek, Z., S. S. Marennikova, M. Mutumbo, J. H. Nakano, K. M. Paluku, and M. Szczeniowski. 1986. Human monkeypox: a study of 2,510 contacts of 214 patients. J. Infect. Dis.154:551-555.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.virol.2005.08.008","volume":"343","year":"2005","unstructured":"Jones-Trower, A., A. Garcia, C. A. Meseda, Y. He, C. Weiss, A. Kumar, J. P. Weir, and M. Merchlinsky. 2005. Identification and preliminary characterization of vaccinia virus (Dryvax) antigens recognized by vaccinia immune globulin. Virology343:128-140.","journal-title":"Virology"},{"key":"e_1_3_2_20_2","first-page":"129","volume":"281","year":"2007","unstructured":"Karupiah, G., V. Panchanathan, I. Sakala, and G. Chaudhri. 2007. Genetic resistance to smallpox; lessons from mouse. Novartis Found. Symp.281:129-140.","journal-title":"Novartis Found. Symp."},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1016\/j.vaccine.2006.03.087","volume":"24","year":"2006","unstructured":"Kenner, J., F. Cameron, C. Empig, D. V. Jobes, and M. Gurwith. 2006. LC16m8: an attenuated smallpox vaccine. Vaccine24:7009-7022.","journal-title":"Vaccine"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"4152","DOI":"10.1073\/pnas.0406671102","volume":"102","year":"2005","unstructured":"Kidokoro, M., M. Tashiro, and H. Shida. 2005. Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8. Proc. Natl. Acad. Sci. USA102:4152-4157.","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1006\/viro.2000.0750","volume":"280","year":"2001","unstructured":"Law, M., and G. L. Smith. 2001. Antibody neutralization of the extracellular enveloped form of vaccinia virus. Virology280:132-142.","journal-title":"Virology"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1086\/518793","volume":"196","year":"2007","unstructured":"Lawrence, S. J., K. R. Lottenbach, F. K. Newman, R. M. Buller, C. J. Bellone, J. J. Chen, G. H. Cohen, R. J. Eisenberg, R. B. Belshe, S. L. Stanley, Jr., and S. E. Frey. 2007. Antibody responses to vaccinia membrane proteins after smallpox vaccination. J. Infect. Dis.196:220-229.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1086\/376557","volume":"188","year":"2003","unstructured":"Manischewitz, J., L. R. King, N. A. Bleckwenn, J. Shiloach, R. Taffs, M. Merchlinsky, N. Eller, M. G. Mikolajczyk, D. J. Clanton, T. Monath, R. A. Weltzin, D. E. Scott, and H. Golding. 2003. Development of a novel vaccinia-neutralization assay based on reporter-gene expression. J. Infect. Dis.188:440-448.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_26_2","first-page":"375","volume":"167","year":"1978","unstructured":"Mayr, A., H. Stickl, H. K. Muller, K. Danner, and H. Singer. 1978. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism. Zentralbl. Bakteriol. B167:375-390. (In German.)","journal-title":"Zentralbl. Bakteriol. B"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1086\/344234","volume":"186","year":"2002","unstructured":"Meseda, C. A., K. L. Elkins, M. J. Merchlinsky, and J. P. Weir. 2002. Prime-boost immunization with DNA and modified vaccinia virus Ankara vectors expressing herpes simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA vaccine alone. J. Infect. Dis.186:1065-1073.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.virol.2005.06.002","volume":"339","year":"2005","unstructured":"Meseda, C. A., A. D. Garcia, A. Kumar, A. E. Mayer, J. Manischewitz, L. R. King, H. Golding, M. Merchlinsky, and J. P. Weir. 2005. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model. Virology339:164-175.","journal-title":"Virology"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.18.11873-11891.2005"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1016\/j.vaccine.2004.02.034","volume":"22","year":"2004","unstructured":"Pulford, D. J., A. Gates, S. H. Bridge, J. H. Robinson, and D. Ulaeto. 2004. Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB\/c mice from a lethal intranasal poxvirus challenge. Vaccine22:3358-3366.","journal-title":"Vaccine"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/nm1457","volume":"12","year":"2006","unstructured":"Putz, M. M., C. M. Midgley, M. Law, and G. L. Smith. 2006. Quantification of antibody responses against multiple antigens of the two infectious forms of vaccinia virus provides a benchmark for smallpox vaccination. Nat. Med.12:1310-1315.","journal-title":"Nat. Med."},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1056\/NEJMoa032299","volume":"350","year":"2004","unstructured":"Reed, K. D., J. W. Melski, M. B. Graham, R. L. Regnery, M. J. Sotir, M. V. Wegner, J. J. Kazmierczak, E. J. Stratman, Y. Li, J. A. Fairley, G. R. Swain, V. A. Olson, E. K. Sargent, S. C. Kehl, M. A. Frace, R. Kline, S. L. Foldy, J. P. Davis, and I. K. Damon. 2004. The detection of monkeypox in humans in the Western Hemisphere. N. Engl. J. Med.350:342-350.","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02642-05"},{"key":"e_1_3_2_34_2","first-page":"244","volume":"1","year":"1999","unstructured":"Smerdou, C., and P. Liljestrom. 1999. Non-viral amplification systems for gene transfer: vectors based on alphaviruses. Curr. Opin. Mol. Ther.1:244-251.","journal-title":"Curr. Opin. Mol. Ther."},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.2.1092-1098.1999"},{"key":"e_1_3_2_36_2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/978-1-4615-5331-1_51","volume":"440","year":"1998","unstructured":"Smith, G. L., and A. Vanderplasschen. 1998. Extracellular enveloped vaccinia virus. Entry, egress, and evasion. Adv. Exp. Med. Biol.440:395-414.","journal-title":"Adv. Exp. Med. Biol."},{"key":"e_1_3_2_37_2","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1099\/0022-1317-83-12-2915","volume":"83","year":"2002","unstructured":"Smith, G. L., A. Vanderplasschen, and M. Law. 2002. The formation and function of extracellular enveloped vaccinia virus. J. Gen. Virol.83:2915-2931.","journal-title":"J. Gen. Virol."},{"key":"e_1_3_2_38_2","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/0264-410X(94)90215-1","volume":"12","year":"1994","unstructured":"Sugimoto, M., and K. Yamanouchi. 1994. Characteristics of an attenuated vaccinia virus strain, LC16m0, and its recombinant virus vaccines. Vaccine12:675-681.","journal-title":"Vaccine"},{"key":"e_1_3_2_39_2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/0042-6822(91)90480-Y","volume":"181","year":"1991","unstructured":"Takahashi-Nishimaki, F., S. Funahashi, K. Miki, S. Hashizume, and M. Sugimoto. 1991. Regulation of plaque size and host range by a vaccinia virus gene related to complement system proteins. Virology181:158-164.","journal-title":"Virology"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00601-06"},{"key":"e_1_3_2_41_2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1084\/jem.20041912","volume":"201","year":"2005","unstructured":"Tscharke, D. C., G. Karupiah, J. Zhou, T. Palmore, K. R. Irvine, S. M. Haeryfar, S. Williams, J. Sidney, A. Sette, J. R. Bennink, and J. W. Yewdell. 2005. Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines. J. Exp. Med.201:95-104.","journal-title":"J. Exp. Med."},{"key":"e_1_3_2_42_2","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.micinf.2005.02.004","volume":"7","year":"2005","unstructured":"Viner, K. M., and S. N. Isaacs. 2005. Activity of vaccinia virus-neutralizing antibody in the sera of smallpox vaccinees. Microbes Infect.7:579-583.","journal-title":"Microbes Infect."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00040-09","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00040-09","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T15:55:19Z","timestamp":1627574119000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00040-09"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["10.1128\/CVI.00040-09"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00040-09","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9]]},"assertion":[{"value":"2009-01-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-06-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}